Matches in SemOpenAlex for { <https://semopenalex.org/work/W4307717505> ?p ?o ?g. }
- W4307717505 endingPage "109334" @default.
- W4307717505 startingPage "109334" @default.
- W4307717505 abstract "Breast cancer, the most common cancer in women worldwide, is curable in ∼ 70-80 % of patients with early-stage, non-metastatic disorder. However, advanced breast cancer with distant organ metastases is incurable with available therapeutics. Thus, scientists have sought emerging strategies for treating metastatic breast cancers., Immune checkpoint inhibitors (ICIs) have represented a significant development in breast cancer immunotherapy. Now, targeting immune checkpoint molecules (e.g., programmed cell death protein 1 (PD-1) and programmed cell death ligand 1 (PD-L1)) have attracted increasing attention in the context of breast cancer therapy, chiefly triple-negative breast cancer (TNBC). Atezolizumab, a humanized IgG1 monoclonal antibody (mAb), has been designed to interfere with the binding of the PD-L1 ligand to its receptor. Targeting PD-L1 using atezolizumab potentiates T-cell responses to the tumor and consequently boosts tumor responses. The results of the IMpassion130 trial have recently led to the approval of the combination of atezolizumab and nab-paclitaxel to treat unresectable locally advanced or metastatic patients with PD-L1-positive TNBC. Herein, we summarize the clinical efficacy of atezolizumab in treating breast cancer and briefly discuss the possible immune-related adverse events (irAEs)." @default.
- W4307717505 created "2022-11-05" @default.
- W4307717505 creator A5004347510 @default.
- W4307717505 creator A5015343359 @default.
- W4307717505 creator A5034516978 @default.
- W4307717505 creator A5040553870 @default.
- W4307717505 creator A5048221888 @default.
- W4307717505 creator A5060336748 @default.
- W4307717505 creator A5070292641 @default.
- W4307717505 creator A5082445255 @default.
- W4307717505 date "2022-12-01" @default.
- W4307717505 modified "2023-10-13" @default.
- W4307717505 title "Recent advances in atezolizumab-based programmed death-ligand 1 (PD-L1) blockade therapy for breast cancer" @default.
- W4307717505 cites W1488814076 @default.
- W4307717505 cites W1601776161 @default.
- W4307717505 cites W1975919516 @default.
- W4307717505 cites W2032605043 @default.
- W4307717505 cites W2083697259 @default.
- W4307717505 cites W2096149428 @default.
- W4307717505 cites W2169344919 @default.
- W4307717505 cites W2339631364 @default.
- W4307717505 cites W2416120277 @default.
- W4307717505 cites W2558960817 @default.
- W4307717505 cites W2565577774 @default.
- W4307717505 cites W2592052792 @default.
- W4307717505 cites W2600285053 @default.
- W4307717505 cites W2618077299 @default.
- W4307717505 cites W2621295461 @default.
- W4307717505 cites W2625173665 @default.
- W4307717505 cites W2734670400 @default.
- W4307717505 cites W2738879667 @default.
- W4307717505 cites W2744067212 @default.
- W4307717505 cites W2747016053 @default.
- W4307717505 cites W2750317630 @default.
- W4307717505 cites W2750541839 @default.
- W4307717505 cites W2761575442 @default.
- W4307717505 cites W2769859703 @default.
- W4307717505 cites W2794044007 @default.
- W4307717505 cites W2802513930 @default.
- W4307717505 cites W2804157113 @default.
- W4307717505 cites W2808674607 @default.
- W4307717505 cites W2884332748 @default.
- W4307717505 cites W2889746019 @default.
- W4307717505 cites W2889968153 @default.
- W4307717505 cites W2897422388 @default.
- W4307717505 cites W2897523860 @default.
- W4307717505 cites W2900929264 @default.
- W4307717505 cites W2903279629 @default.
- W4307717505 cites W2925030036 @default.
- W4307717505 cites W2937318637 @default.
- W4307717505 cites W2943180760 @default.
- W4307717505 cites W2946317931 @default.
- W4307717505 cites W2957094860 @default.
- W4307717505 cites W2971987441 @default.
- W4307717505 cites W2979775428 @default.
- W4307717505 cites W2980868069 @default.
- W4307717505 cites W2982130750 @default.
- W4307717505 cites W2990398119 @default.
- W4307717505 cites W3004823899 @default.
- W4307717505 cites W3006455065 @default.
- W4307717505 cites W3006693642 @default.
- W4307717505 cites W3009188653 @default.
- W4307717505 cites W3014206773 @default.
- W4307717505 cites W3022747490 @default.
- W4307717505 cites W3029666511 @default.
- W4307717505 cites W3030487289 @default.
- W4307717505 cites W3032932212 @default.
- W4307717505 cites W3036692211 @default.
- W4307717505 cites W3037293601 @default.
- W4307717505 cites W3039824324 @default.
- W4307717505 cites W3041267635 @default.
- W4307717505 cites W3077251618 @default.
- W4307717505 cites W3081561806 @default.
- W4307717505 cites W3087393791 @default.
- W4307717505 cites W3088588360 @default.
- W4307717505 cites W3091206066 @default.
- W4307717505 cites W3118950316 @default.
- W4307717505 cites W3127482120 @default.
- W4307717505 cites W3128792891 @default.
- W4307717505 cites W3132496360 @default.
- W4307717505 cites W3133505191 @default.
- W4307717505 cites W3135463968 @default.
- W4307717505 cites W3156313594 @default.
- W4307717505 cites W3160175777 @default.
- W4307717505 cites W3161258176 @default.
- W4307717505 cites W3164568244 @default.
- W4307717505 cites W3173705400 @default.
- W4307717505 cites W3175173749 @default.
- W4307717505 cites W3176200586 @default.
- W4307717505 cites W3184322803 @default.
- W4307717505 cites W3195137671 @default.
- W4307717505 cites W3199275563 @default.
- W4307717505 cites W3212606565 @default.
- W4307717505 cites W3214046825 @default.
- W4307717505 cites W3215788489 @default.
- W4307717505 cites W4205724345 @default.
- W4307717505 cites W4211005384 @default.
- W4307717505 cites W4211007805 @default.